Local Ablation Therapy for Hepatocellular Carcinoma: Clinical Significance of Tumor Size, Location, and Biology.
Journal
Investigative radiology
ISSN: 1536-0210
Titre abrégé: Invest Radiol
Pays: United States
ID NLM: 0045377
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
6
7
2024
Statut:
aheadofprint
Résumé
Local ablation therapy, encompassing radiofrequency ablation (RFA), microwave ablation, and cryoablation, has emerged as a crucial strategy for managing small hepatocellular carcinomas (HCCs), complementing liver resection and transplantation. This review delves into the clinical significance of tumor size, location, and biology in guiding treatment decisions for HCCs undergoing local ablation therapy, with a focus on tumors smaller than 3 cm. Tumor size significantly influences treatment outcomes, with larger tumors associated with poorer local tumor control due to challenges in creating sufficient ablative margins and the likelihood of microvascular invasion and peritumoral satellite nodules. Advanced ablation techniques such as centripetal or no-touch RFA using multiple electrodes, cryoablation using multiple cryoprobes, and microwave ablation offer diverse options for HCC treatment. Notably, no-touch RFA demonstrates superior local tumor control compared with conventional RFA by achieving sufficient ablative margins, making it particularly promising for hepatic dome lesions or tumors with aggressive biology. Laparoscopic RFA proves beneficial for treating anterior subphrenic HCCs, whereas artificial pleural effusion-assisted RFA is effective for controlling posterior subphrenic HCCs. However, surgical resection generally offers better survival outcomes for periportal HCCs compared with RFA. Cryoablation exhibits a lower incidence of vascular or biliary complications than RFA for HCCs adjacent to perivascular or periductal regions. Additionally, aggressive tumor biology, such as microvascular invasion, can be predicted using magnetic resonance imaging findings and serum tumor markers. Aggressive HCC subtypes frequently exhibit Liver Imaging Reporting and Data System M features on magnetic resonance imaging, aiding in prognosis. A comprehensive understanding of tumor size, location, and biology is imperative for optimizing the benefits of local ablation therapy in managing HCCs.
Identifiants
pubmed: 38970255
doi: 10.1097/RLI.0000000000001100
pii: 00004424-990000000-00231
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–693.
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol. 2022;23:1126–1240.
Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–1965.
Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400:1345–1362.
Gupta P, Maralakunte M, Kumar-M P, et al. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis. Eur Radiol. 2021;31:5400–5408.
Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796–802.
Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology. 2021;73:137–149.
Ikeda K, Seki T, Umehara H, et al. Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol. 2007;31:485–491.
Liao M, Zhong X, Zhang J, et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: a prospective randomized trial. J Surg Oncol. 2017;115:971–979.
Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–89.
Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019;70:866–873.
Peng Z-W, Zhang Y-J, Chen M-S, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–432.
Zaitoun MMA, Elsayed SB, Zaitoun NA, et al. Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3- < 5 cm. Int J Hyperthermia. 2021;38:248–256.
Lee DH, Kim JW, Lee JM, et al. Laparoscopic liver resection versus percutaneous radiofrequency ablation for small single nodular hepatocellular carcinoma: comparison of treatment outcomes. Liver Cancer. 2021;10:25–37.
Lee MW, Kang D, Lim HK, et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol. 2020;30:2391–2400.
Song KD, Lim HK, Rhim H, et al. Hepatic resection vs percutaneous radiofrequency ablation of hepatocellular carcinoma abutting right diaphragm. World J Gastrointest Oncol. 2019;11:227–237.
Ko SE, Lee MW, Ahn S, et al. Laparoscopic hepatic resection versus laparoscopic radiofrequency ablation for subcapsular hepatocellular carcinomas smaller than 3 cm: analysis of treatment outcomes using propensity score matching. Korean J Radiol. 2022;23:615–624.
Ko SE, Lee MW, Min JH, et al. Laparoscopic radiofrequency ablation of subcapsular hepatocellular carcinomas: risk factors related to a technical failure. Surg Endosc. 2022;36:504–514.
Koda M, Ueki M, Maeda Y, et al. Percutaneous sonographically guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma located under the diaphragm. AJR Am J Roentgenol. 2004;183:583–588.
Lu DSK, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003;14:1267–1274.
Feng Y, Wang L, Lv H, et al. Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis. HPB (Oxford). 2021;23:512–519.
Kang TW, Lim HK, Lee MW, et al. Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation: risk factors and clinical significance. Radiology. 2015;276:274–285.
Kang TW, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: refining the current status based on emerging evidence and future perspectives. World J Gastroenterol. 2018;24:5331–5337.
Mori Y, Tamai H, Shingaki N, et al. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. Hepatol Int. 2009;3:509–515.
Lee S, Kang TW, Cha DI, et al. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes. J Hepatol. 2018;69:70–78.
Han S, Lee MW, Lee YJ, et al. No-touch radiofrequency ablation for early hepatocellular carcinoma: 2023 Korean Society of Image-Guided Tumor Ablation Guidelines. Korean J Radiol. 2023;24:719–728.
Park SJ, Cho EJ, Lee JH, et al. Switching monopolar no-touch radiofrequency ablation using Octopus electrodes for small hepatocellular carcinoma: a randomized clinical trial. Liver Cancer. 2021;10:72–81.
Suh YS, Choi JW, Yoon JH, et al. No-touch vs. conventional radiofrequency ablation using twin internally cooled wet electrodes for small hepatocellular carcinomas: a randomized prospective comparative study. Korean J Radiol. 2021;22:1974–1984.
Lee DH, Lee MW, Kim PN, et al. Outcome of no-touch radiofrequency ablation for small hepatocellular carcinoma: a multicenter clinical trial. Radiology. 2021;301:229–236.
Kim T-H, Lee JM, Lee DH, et al. Can “no-touch” radiofrequency ablation for hepatocellular carcinoma improve local tumor control? Systematic review and meta-analysis. Eur Radiol. 2023;33:545–554.
Jo MG, Lee MW, Ahn S, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma in a recent cohort at a tertiary cancer center: incidence and factors associated with major complications and unexpected hospitalization events. Ultrasonography. 2023;42:41–53.
Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol. 2019;29:654–662.
Ko SE, Lee MW, Rhim H, et al. Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma. Int J Hyperthermia. 2020;37:1354–1361.
Cha SY, Kang TW, Min JH, et al. RF ablation versus cryoablation for small perivascular hepatocellular carcinoma: propensity score analyses of mid-term outcomes. Cardiovasc Intervent Radiol. 2020;43:434–444.
Hu H, Chi JC, Liu R, et al. Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes. Int J Hyperthermia. 2021;38:191–201.
Loy LM, Low HM, Choi J-Y, et al. Variant hepatocellular carcinoma subtypes according to the 2019 WHO classification: an imaging-focused review. AJR Am J Roentgenol. 2022;219:212–223.
Low HM, Lee JM, Tan CH. Prognosis prediction of hepatocellular carcinoma based on magnetic resonance imaging features. Korean J Radiol. 2023;24:660–667.
Rhee H, Kim H, Park YN. Clinico-radio-pathological and molecular features of hepatocellular carcinomas with keratin 19 expression. Liver Cancer. 2020;9:663–681.
Kim JH, Yoon JH, Bae JS, et al. Multiarterial phase acquisition in gadoxetic acid–enhanced liver MRI for the detection of hypervascular hepatocellular carcinoma in high-risk patients: comparison of compressed sensing versus view sharing techniques. Invest Radiol. 2023;58:139–147.
An C, Kim DW, Park Y-N, et al. Single hepatocellular carcinoma: preoperative MR imaging to predict early recurrence after curative resection. Radiology. 2015;276:433–443.
Min JH, Lee MW, Rhim H, et al. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation. Eur Radiol. 2024;34:525–537.
Cha DI, Lee MW, Jeong WK, et al. Rim-arterial enhancing primary hepatic tumors with other targetoid appearance show early recurrence after radiofrequency ablation. Eur Radiol. 2021;31:6555–6567.
Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273:564–571.
Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33:347–354.
Ichikawa S, Goshima S. Gadoxetic acid–enhanced liver MRI: everything you need to know. Invest Radiol. 2024;59:53–68.
Lee S, Kim SH, Lee JE, et al. Preoperative gadoxetic acid–enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. 2017;67:526–534.
Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10:94–106.
Min JH, Lee MW, Park HS, et al. Interobserver variability and diagnostic performance of gadoxetic acid–enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma. Radiology. 2020;297:573–581.
Yoo J, Lee MW, Lee DH, et al. Evaluation of a serum tumour marker–based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int. 2020;40:1189–1200.
Imai K, Yamashita YI, Yusa T, et al. Microvascular invasion in small-sized hepatocellular carcinoma: significance for outcomes following hepatectomy and radiofrequency ablation. Anticancer Res. 2018;38:1053–1060.
Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol. 2016;64:594–600.